{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T04:17:37Z","timestamp":1791001057961,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T00:00:00Z","timestamp":1596153600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T00:00:00Z","timestamp":1596153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s10637-020-00975-6","type":"journal-article","created":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T12:03:54Z","timestamp":1596197034000},"page":"163-174","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3331-4095","authenticated-orcid":false,"given":"Geoffrey I.","family":"Shapiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"LoRusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C.","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luna","family":"Musib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibing","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Wongchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilsung","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Premal","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris T.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Sanabria-Bohorquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond D.","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna C.","family":"Bendell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,31]]},"reference":[{"key":"975_CR1","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1126\/science.1072682","volume":"298","author":"GL Johnson","year":"2002","unstructured":"Johnson GL, Lapadat R (2002) Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298:1911\u20131912","journal-title":"Science"},{"key":"975_CR2","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1038\/sj.onc.1210422","volume":"26","author":"PJ Roberts","year":"2007","unstructured":"Roberts PJ, Der CJ (2007) Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26:3291\u20133310","journal-title":"Oncogene"},{"key":"975_CR3","doi-asserted-by":"publisher","first-page":"7996","DOI":"10.1073\/pnas.1509123112","volume":"112","author":"X Nan","year":"2015","unstructured":"Nan X, Tamguney TM, Collisson EA, Lin LJ, Pitt C, Galeas J, Lewis S, Gray JW, McCormick F, Chu S (2015) Ras-GTP dimers activate the mitogen-activated protein kinase (MAPK) pathway. Proc Natl Acad Sci U S A 112:7996\u20138001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"975_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrc969","volume":"3","author":"J Downward","year":"2003","unstructured":"Downward J (2003) Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3:11\u201322","journal-title":"Nat Rev Cancer"},{"key":"975_CR5","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1093\/annonc\/mdw261","volume":"27","author":"DP Modest","year":"2016","unstructured":"Modest DP, Ricard I, Heinemann V, Hegewisch-Becker S, Schmiegel W, Porschen R, Stintzing S, Graeven U, Arnold D, von Weikersthal LF, Giessen-Jung C, Stahler A, Schmoll HJ, Jung A, Kirchner T, Tannapfel A, Reinacher-Schick A (2016) Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group. Ann Oncol 27:1746\u20131753","journal-title":"Ann Oncol"},{"key":"975_CR6","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/ijc.2910640412","volume":"64","author":"A Bellacosa","year":"1995","unstructured":"Bellacosa A, de Feo D, Godwin AK, Bell DW, Cheng JQ, Altomare DA, Wan M, Dubeau L, Scambia G, Masciullo V, Ferrandina G, Benedetti Panici P, Mancuso S, Neri G, Testa JR (1995) Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 64:280\u2013285","journal-title":"Int J Cancer"},{"key":"975_CR7","doi-asserted-by":"crossref","unstructured":"Cantley LC (2002) The phosphoinositide 3-kinase pathway. Science (New York, NY). 296:1655-7","DOI":"10.1126\/science.296.5573.1655"},{"key":"975_CR8","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/j.cell.2007.06.009","volume":"129","author":"BD Manning","year":"2007","unstructured":"Manning BD, Cantley LC (2007) AKT\/PKB signaling: navigating downstream. Cell. 129:1261\u20131274","journal-title":"Cell."},{"key":"975_CR9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2174\/156800908783497140","volume":"8","author":"E Tokunaga","year":"2008","unstructured":"Tokunaga E, Oki E, Egashira A, Sadanaga N, Morita M, Kakeji Y, Maehara Y (2008) Deregulation of the AKT pathway in human cancer. Curr Cancer Drug Targets 8:27\u201336","journal-title":"Curr Cancer Drug Targets"},{"key":"975_CR10","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1126\/science.275.5308.1943","volume":"275","author":"J Li","year":"1997","unstructured":"Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275:1943\u20131947","journal-title":"Science"},{"key":"975_CR11","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/ng0497-356","volume":"15","author":"PA Steck","year":"1997","unstructured":"Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DH, Tavtigian SV (1997) Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15:356\u2013362","journal-title":"Nat Genet"},{"key":"975_CR12","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1126\/science.1096502","volume":"304","author":"Y Samuels","year":"2004","unstructured":"Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304:554","journal-title":"Science"},{"key":"975_CR13","doi-asserted-by":"publisher","first-page":"22231","DOI":"10.1073\/pnas.1015245107","volume":"107","author":"CG Fedele","year":"2010","unstructured":"Fedele CG, Ooms LM, Ho M, Vieusseux J, O'Toole SA, Millar EK, Lopez-Knowles E, Sriratana A, Gurung R, Baglietto L, Giles GG, Bailey CG, Rasko JE, Shields BJ, Price JT, Majerus PW, Sutherland RL, Tiganis T, McLean CA, Mitchell CA (2010) Inositol polyphosphate 4-phosphatase II regulates PI3K\/AKT signaling and is lost in human basal-like breast cancers. Proc Natl Acad Sci 107:22231\u201322236","journal-title":"Proc Natl Acad Sci"},{"key":"975_CR14","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ccr.2007.07.014","volume":"12","author":"J Brugge","year":"2007","unstructured":"Brugge J, Hung MC, Mills GB (2007) A new mutational AKTivation in the PI3K pathway. Cancer Cell 12:104\u2013107","journal-title":"Cancer Cell"},{"key":"975_CR15","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/leu.2008.26","volume":"22","author":"LS Steelman","year":"2008","unstructured":"Steelman LS, Abrams SL, Whelan J, Bertrand FE, Ludwig DE, B\u00e4secke J, Libra M, Stivala F, Milella M, Tafuri A, Lunghi P, Bonati A, Martelli AM, McCubrey JA (2008) Contributions of the Raf\/MEK\/ERK, PI3K\/PTEN\/AKT\/mTOR and Jak\/STAT pathways to leukemia. Leukemia 22:686\u2013707","journal-title":"Leukemia"},{"key":"975_CR16","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1016\/j.bbagen.2016.06.016","volume":"1860","author":"N Alonso","year":"2016","unstructured":"Alonso N, Diaz Nebreda A, Monczor F, Gutkind JS, Davio C, Fernandez N, Shayo C (2016) PI3K pathway is involved in ERK signaling cascade activation by histamine H2R agonist in HEK293T cells. Biochim Biophys Acta 1860:1998\u20132007","journal-title":"Biochim Biophys Acta"},{"key":"975_CR17","doi-asserted-by":"publisher","first-page":"245","DOI":"10.4161\/cbt.27541","volume":"5","author":"P Dent","year":"2014","unstructured":"Dent P (2014) Crosstalk between ERK, AKT, and cell survival. Cancer Biol Ther 5:245\u2013246","journal-title":"Cancer Biol Ther"},{"key":"975_CR18","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1158\/1541-7786.MCR-15-0506","volume":"14","author":"JY Kim","year":"2016","unstructured":"Kim JY, Welsh EA, Fang B, Bai Y, Kinose F, Eschrich SA, Koomen JM, Haura EB (2016) Phosphoproteomics reveals MAPK inhibitors enhance MET- and EGFR-driven AKT signaling in KRAS-mutant lung cancer. Mol Cancer Res 14:1019\u20131029","journal-title":"Mol Cancer Res"},{"key":"975_CR19","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/nature04869","volume":"441","author":"RJ Shaw","year":"2006","unstructured":"Shaw RJ, Cantley LC (2006) Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441:424\u2013430","journal-title":"Nature"},{"key":"975_CR20","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s00280-012-1988-6","volume":"71","author":"EF Choo","year":"2013","unstructured":"Choo EF, Ng CM, Berry L, Belvin M, Lewin-Koh N, Merchant M, Salphati L (2013) PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts. Cancer Chemother Pharmacol 71:133\u2013143","journal-title":"Cancer Chemother Pharmacol"},{"key":"975_CR21","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1007\/s10637-016-0374-3","volume":"34","author":"LS Rosen","year":"2016","unstructured":"Rosen LS, LoRusso P, Ma WW, Goldman JW, Weise A, Colevas AD, Adjei A, Yazji S, Shen A, Johnston S, Hsieh HJ, Chan IT, Sikic BI (2016) A first-in-human phase I study to evaluate the MEK1\/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors. Investig New Drugs 34:604\u2013613","journal-title":"Investig New Drugs"},{"key":"975_CR22","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","volume":"17","author":"PA Ascierto","year":"2016","unstructured":"Ascierto PA, McArthur GA, Dr\u00e9no B, Atkinson V, Liszkay G, Di Giacomo AM, Mandal\u00e0 M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Yan Y, Wongchenko M, Chang I, Hsu JJ, Koralek DO, Rooney I, Ribas A, Larkin J (2016) Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol 17:1248\u20131260","journal-title":"Lancet Oncol"},{"key":"975_CR23","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1158\/2159-8290.CD-16-0512","volume":"7","author":"C Saura","year":"2017","unstructured":"Saura C, Roda D, Rosell\u00f3 S, Oliveira M, Macarulla T, P\u00e9rez-Fidalgo JA, Morales-Barrera R, Sanchis-Garc\u00eda JM, Musib L, Budha N, Zhu J, Nannini M, Chan WY, Sanabria Boh\u00f3rquez SM, Meng RD, Lin K, Yan Y, Patel P, Baselga J, Tabernero J, Cervantes A (2017) A first-in-human phase I study of the ATP-competitive AKT inhibitor ipatasertib demonstrates robust and safe targeting of AKT in patients with solid tumors. Cancer Discov 7:102\u2013113","journal-title":"Cancer Discov"},{"key":"975_CR24","unstructured":"Cobimetinib [package insert], South San Francisco, CA: Genentech, Inc.: 2015"},{"key":"975_CR25","doi-asserted-by":"crossref","unstructured":"Nannini MA, Hong R, Lee BB, Arrazante A, Kassees R, Lin J, Degtyarev M, Sampath D, Lin Kui (2012) Combined targeting of Akt and MEK with the Akt inhibitor GDC-0068 and MEK inhibitor GDC-0973 demonstrates synergistic anti-tumor effects. Cancer Res 72(8 Suppl):Abstract nr 873","DOI":"10.1158\/1538-7445.AM2012-873"},{"key":"975_CR26","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ccr.2014.05.020","volume":"26","author":"SR Vora","year":"2014","unstructured":"Vora SR, Juric D, Kim N, Mino-Kenudson M, Huynh T, Costa C, Lockerman EL, Pollack SF, Liu M, Li X, Lehar J, Wiesmann M, Wartmann M, Chen Y, Cao ZA, Pinzon-Ortiz M, Kim S, Schlegel R, Huang A, Engelman JA (2014) CDK4\/6 inhibitors sensitize PIK3CA mutant breast cancers to PI3K inhibitors. Cancer Cell 26:136\u2013149","journal-title":"Cancer Cell"},{"key":"975_CR27","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.ygyno.2019.09.024","volume":"155","author":"SN Westin","year":"2019","unstructured":"Westin SN, Sill MW, Coleman RL, Waggoner S, Moore KN, Mathews CA, Martin LP, Modesitt SC, Lee S, Ju Z, Mills GB, Schilder RJ, Fracasso PM, Birrer MJ, Aghajanian C (2019) Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: an NRG oncology\/GOG study. Gynecol Oncol 155:420\u2013428","journal-title":"Gynecol Oncol"},{"key":"975_CR28","doi-asserted-by":"crossref","unstructured":"Ramaswamy B, Mrozek E, Lustberg M, Wesolowski R, Layman R, Abdel-Rasoul M, Timmers C, Patrick R, Sexton J, Macrae E, Shapiro C, Budd T, Harris L, Isaacs C, Ismail-Khan R, Dees C, Poklepovic A, Grever M, Cehn H, Villalona M, Carson W (2016) NCI 9455: phase II study of trametinib followed by trametinib plus AKT inhibitor GSK2141795 in patients with advanced triple-negative breast cancer. Cancer res 76:LB-216","DOI":"10.1158\/1538-7445.AM2016-LB-216"},{"key":"975_CR29","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1158\/1078-0432.CCR-14-1901","volume":"21","author":"AW Tolcher","year":"2015","unstructured":"Tolcher AW, Khan K, Ong M, Banerji U, Papadimitrakopoulou V, Gandara DR, Patnaik A, Baird RD, Olmos D, Garrett CR, Skolnik JM, Rubin EH, Smith PD, Huang P, Learoyd M, Shannon KA, Morosky A, Tetteh E, Jou YM, Papadopoulos KP, Moreno V, Kaiser B, Yap TA, Yan L, de Bono JS (2015) Antitumor activity in RAS-driven tumors by blocking AKT and MEK. Clin Cancer Res 21:739\u2013748","journal-title":"Clin Cancer Res"},{"key":"975_CR30","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/pcmr.12644","volume":"31","author":"AP Algazi","year":"2018","unstructured":"Algazi AP, Esteve-Puig R, Nosrati A, Hinds B, Hobbs-Muthukumar A, Nandoskar P, Ortiz-Urda S, Chapman PB, Daud A (2018) Dual MEK\/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in patients with NRAS-mutant and wild-type melanoma. Pigment Cell Melanoma Res 31:110\u2013114","journal-title":"Pigment Cell Melanoma Res"},{"key":"975_CR31","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ygyno.2019.05.003","volume":"154","author":"JF Liu","year":"2019","unstructured":"Liu JF, Gray KP, Wright AA, Campos S, Konstantinopoulos PA, Peralta A, MacNeill K, Morrissey S, Whalen C, Dillon D, Matulonis UA (2019) Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer. Gynecol Oncol 154:95\u2013101","journal-title":"Gynecol Oncol"},{"key":"975_CR32","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.3390\/cancers11091318","volume":"11","author":"D Cretella","year":"2019","unstructured":"Cretella D, Digiacomo G, Giovannetti E, Cavazzoni A (2019) PTEN alterations as a potential mechanism for tumor cell escape from PD-1\/PD-L1 inhibition. Cancers 11:1318","journal-title":"Cancers"},{"key":"975_CR33","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.celrep.2019.03.066","volume":"27","author":"H Choi","year":"2019","unstructured":"Choi H, Deng J, Li S, Silk T, Dong L, Brea EJ, Houghton S, Redmond D, Zhong H, Boiarsky J, Akbay EA, Smith PD, Merghoub T, Wong KK, Wolchok JD (2019) Pulsatile MEK inhibition improves anti-tumor immunity and T cell function in murine KRAS mutant lung cancer. Cell Rep 27:806\u2013819","journal-title":"Cell Rep"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-020-00975-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-020-00975-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-020-00975-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:53:19Z","timestamp":1678510399000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-020-00975-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,31]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["975"],"URL":"https:\/\/doi.org\/10.1007\/s10637-020-00975-6","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,31]]},"assertion":[{"value":"11 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"GIS: GIS has received research funding from Eli Lilly, Merck KGaA\/EMD-Serono, Merck, and Sierra Oncology. He has served on advisory boards for Pfizer, Eli Lilly, G1 Therapeutics, Roche, Merck KGaA\/EMD-Serono, Sierra Oncology, Bicycle Therapeutics, Fusion Pharmaceuticals, Cybrexa Therapeutics, Astex, Almac, Ipsen, Bayer, Angiex, Daiichi Sankyo, Seattle Genetics, Boehringer Ingelheim, ImmunoMet, Asana, Artios, Atrin and Concarlo Holdings. In addition, he holds a patent entitled, \u201cDosage regimen for sapacitabine and seliciclib,\u201d also issued to Cyclacel Pharmaceuticals, and a pending patent, entitled, \u201cCompositions and Methods for Predicting Response and Resistance to CDK4\/6 Inhibition,\u201d together with Liam Cornell.PL: None.DCC: Consulting\/Advisory for Nektar, Pfizer, Torque, HUYA, and PureTech, relationship with self.LM: Employee of Genentech, Inc., shareholder of F. Hoffmann La Roche, Ltd.YY: Employee of Genentech, Inc., shareholder of F. Hoffmann La Roche, Ltd.MW: Employee of Genentech, Inc., shareholder of F. Hoffmann La Roche, Ltd.IC: Employee of Genentech, Inc., shareholder of F. Hoffmann La Roche, Ltd.; Employee of Celltrion, Inc., shareholder of Celltrion, Inc.PP: Employee of Genentech, Inc., shareholder of F. Hoffmann La Roche, Ltd.ITC: Employee of Genentech, Inc., shareholder of F. Hoffmann La Roche, Ltd.RDM: Employee of Genentech, Inc., shareholder of F. Hoffmann La Roche, Ltd.JCB: Research Funding - All to Institution: Gilead, Genentech\/Roche, BMS, Five Prime, Lilly, Merck, MedImmune, Celgene, EMD Serono, Taiho, Macrogenics, GSK, Novartis, OncoMed, LEAP, TG Therapeutics, AstraZeneca, BI, Daiichi Sankyo, Bayer, Incyte, Apexigen, Koltan, SynDevRex, Forty Seven, AbbVie, Array, Onyx, Sanofi, Takeda, Eisai, Celldex, Agios, Cytomx, Nektar, ARMO, Boston Biomedical, Ipsen, Merrimack, Tarveda, Tyrogenex, Oncogenex, Marshall Edwards, Pieris, Mersana, Calithera, Blueprint, Evelo, FORMA, Merus, Jacobio, Effector, Novocare, Arrys, Tracon, Sierra, Innate, Arch Oncology, Prelude Oncology, Unum Therapeutics, Vyriad, Harpoon, ADC, Amgen, Pfizer, Millennium, Imclone, Acerta Pharma, Rgenix, Bellicum, Gossamer Bio, Arcus Bio, Seattle Genetics, TempestTx, Shattuck Labs. Consulting \/Advisory Role - All to Institution: Gilead, Genentech\/Roche, BMS, Five Prime, Lilly, Merck, MedImmune, Celgene, Taiho, Macrogenics, GSK, Novartis, OncoMed, LEAP, TG Therapeutics, AstraZeneca, BI, Daiichi Sankyo, Bayer, Incyte, Apexigen, Array, Sanofi, ARMO, Ipsen, Merrimack, Oncogenex, FORMA, Arch Oncology, Prelude Therapeutics, Phoenix Bio, Cyteir, Molecular Partners, Innate, Torque, Tizona, Janssen, Tolero, TD2 (Translational Drug Development), Amgen, Seattle Genetics, Moderna Therapeutics, Tanabe Research Laboratories, Beigene, Continuum Clinical, Agois. Food\/Beverage\/Travel: Gilead, Genentech\/Roche, BMS, Lilly, Merck, MedImmune, Celgene, Taiho, Novartis, OncoMed, BI, ARMO, Ipsen, Oncogenex, FORMA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted at 6 institutions in the United States and Australia in accordance with the 1964 Helsinki declaration and it later amendments, as well as the International Conference on Harmonization E6 Guidelines for Good Clinical Practice. The study was approved by regulatory and ethics committees at each institution and was registered at Clinicaltrials.gov, NCT01562275. Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}